导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.30% | 1574/4773 |
| 近一周 | -0.01% | 418/5458 |
| 近一月 | 1.39% | 543/5421 |
| 近一季 | 0.03% | 1060/5205 |
| 近半年 | -12.27% | 3806/4920 |
| 近一年 | 10.40% | 1013/4361 |
| 近两年 | 44.60% | 1712/2954 |
| 近三年 | 29.26% | 1097/2253 |
| 成立以来 | 95.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
8.82% 101/4961 |
-6.22% 3675/5312 |
- - |
- - |
| 2025 | 15.69% 2519/4813 |
-1.79% 2778/3635 |
1.35% 2370/4076 |
9.76% 3336/4524 |
5.90% 391/4813 |
| 2024 | 16.75% 768/3463 |
7.06% 264/2808 |
1.31% 479/3014 |
9.90% 2658/3129 |
-2.05% 1939/3463 |
| 2023 | -0.93% 480/2656 |
12.31% 300/2280 |
0.96% 258/2385 |
-6.37% 1472/2515 |
-6.68% 1875/2655 |
| 2022 | -12.37% 279/2207 |
-7.85% 256/1919 |
5.06% 943/2016 |
-11.76% 576/2113 |
2.59% 890/2208 |
| 2021 | 15.06% 313/1822 |
5.15% 120/1255 |
4.77% 847/1330 |
5.64% 263/1466 |
-1.14% 1316/1822 |
| 2020 | - - |
- - |
0.46% 1001/1067 |
10.95% 492/1164 |
11.98% 506/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证国企带路发起式联接A VS. 长安沪深300非周期A(740101) |